当前位置: 首页 > 详情页

Association between expression of nuclear receptor co-activator 5 protein and prognosis in postoperative patients with osteosarcoma

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Department of Orthopedics, Second Affiliated Hospital of Suzhou University, Suzhou, Jiangsu 215004 [2]Departments of Orthopedics , The First People's Hospital of Yancheng City, Yancheng, Jiangsu 224005, P.R. China [3]Departments of Laboratory Medicine, The First People's Hospital of Yancheng City, Yancheng, Jiangsu 224005, P.R. China
出处:
ISSN:

关键词: human osteosarcoma nuclear receptor co-activator 5 prognosis immunohistochemistry

摘要:
The aim of the present study was to investigate the association between the expression of nuclear receptor co-activator 5 protein (NCOA5) and the prognosis of postoperative patients with osteosarcoma. Human osteosarcoma samples were collected from 145 patients and normal bone tissues were collected from 100 individuals as controls. Immunohistochemistry (IHC) and reverse transcription-polymerase chain reaction (RT-PCR) were employed to measure the levels of NCOA5 protein in cases of human osteosarcoma. The results from the RT-PCR analysis demonstrated that the positive rate of NCOA5 mRNA expression in human osteosarcoma was 17.24% (25/145). The positive rate in normal bone tissues was 84.00% (84/100), which was significantly higher compared with that of human osteosarcoma tissues (chi(2)=33.166; P<0.001). IHC staining indicated that the positive rate of NCOA5 protein in the osteosarcoma samples was 26.21% (38/145). The positive rate in normal bone tissues was 82.00% (82/100), which was significantly increased compared with that of human osteosarcoma tissues (chi(2)=28.166; P<0.001). NCOA5 mRNA and protein expression levels were consistent in human osteosarcoma tissues, and were lower than in control tissues. The expression of NCOA5 was low in human osteosarcoma tissues, while it was high in normal bone tissues. These low NCOA5 expression levels were associated with postoperative survival of human osteosarcoma.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2016]版:
Q4 ONCOLOGY
最新[2023]版:
Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Department of Orthopedics, Second Affiliated Hospital of Suzhou University, Suzhou, Jiangsu 215004 [2]Departments of Orthopedics , The First People's Hospital of Yancheng City, Yancheng, Jiangsu 224005, P.R. China
共同第一作者:
通讯作者:
通讯机构: [*1]Department of Orthopedics, Second Affiliated Hospital of Suzhou University, 1055 Sanxiang Road, Suzhou, Jiangsu 215004, P.R. China [*2]Department of Laboratory Medicine, The First People's Hospital of Yancheng City, 166 Yulong Road, Yancheng, Jiangsu 224005, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院